Why ADMA Biologics Stock Is Soaring Today
Shares of ADMA Biologics (NASDAQ: ADMA) were soaring 17.2% higher as of 11:34 a.m. EST on Thursday. The big jump came after the biotech announced its preliminary 2019 Q4 results and provided a strategic outlook for 2020.
ADMA expects to report Q4 revenue of $11.9 million, nearly triple the revenue of $4.1 million posted in the prior-year period. For full-year 2019, the company's preliminary revenue totaled $29.2 million, up 72% year over year. ADMA also listed several strategic priorities for 2020, including expanding its commercial launches of Bivigam and Asceniv.
Image source: Getty Images.
Source Fool.com
